Skip to main content
Addgene

pDN80
(Plasmid #61349)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 61349 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pmCherry-N1
  • Backbone manufacturer
    Clontech
  • Vector type
    Mammalian Expression
  • Promoter CMV
  • Tags / Fusion Proteins
    • mCherry (C terminal on backbone)
    • AsLOV2 wt (C terminal on backbone)

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Cloning Information

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

LINuS-flex was designed to contain a spacer sequence flanked by BsmBI restriction sites between the VP64 transactivation domain and mCherry enabling scarless introduction of any NES sequence by standard oligo cloning.
A second spacer sequence flanked by BsaI restriction sites is located behind the truncated AsLOV2 domain and enables scarless introduction of any NLS sequence by standard oligo cloning.
Unique BamHI and SpeI sites further enable the exchange of the LexA DBD-MBP-VP64 fragment by any sequence of interest.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pDN80 was a gift from Barbara Di Ventura & Roland Eils (Addgene plasmid # 61349 ; http://n2t.net/addgene:61349 ; RRID:Addgene_61349)
  • For your References section:

    Engineering light-inducible nuclear localization signals for precise spatiotemporal control of protein dynamics in living cells. Niopek D, Benzinger D, Roensch J, Draebing T, Wehler P, Eils R, Di Ventura B. Nat Commun. 2014 Jul 14;5:4404. doi: 10.1038/ncomms5404. 10.1038/ncomms5404 PubMed 25019686